美罗华联合化疗治疗B细胞非霍奇金淋巴瘤46例临床分析

Combination chemotherapy with rituximah for B-cell non-Hodgkin lymphom

目的探讨美罗华联合化疗治疗B细胞非霍奇金淋巴瘤的临床疗效。方法选择2004年1月-2009年11月收治于我院的B细胞非霍奇金淋巴瘤患者92例，随机分为观察组（46例）和对照组（46例），观察组采用美罗华联合CHOP化疗治疗，对照组采用单纯CHOP方案化疗，比较两组治疗效果。结果观察组总有效率89．1％，对照组总有效率88．7％，比较差异有显著性（P〈0．05）；观察组不良反应7例，对照组发生8例，比较差异无显著性（P〉0．05）。结论美罗华联合化疗治疗B细胞非霍奇金淋巴瘤，具有临床疗效好、不良反应少、生存率高等优点，值得推广应用。

Objective To evaluate the efficacy of combined chemotherapy with rituximab for patients with B-cell non-Hodgkin＇s lymphoma. Methods 92 patients with B-cell non-Hodgkin＇s lymphoma hospitalized from January 2004 to November 2009 were randomly assigned to receive either CHOP plus rituximab （study group） or CHOP alone （control group）. The efficacy was compared between the two groups. Results After 2 course of treatment, observe groups have better than control groups in total effective rate and survival rate of one year after treatment. Conclusions Combination therapy with rituximab for B-cell non-Hodgkin＇s lymphoma has a better clinical efficacy, fewer adverse reactions, and a higher survival rate. It is worth popularizing.